10-Q: Climb Bio Reports Q3 2024 Results, Advances Budoprutug Development

Climb Bio, formerly Eliem Therapeutics, reports its third quarter 2024 results, highlighting a strategic shift to immune-mediated diseases and progress in the development of its lead candidate, budoprutug.

Summary

• Climb Bio, previously known as Eliem Therapeutics, has shifted its focus to developing therapeutics for immune-mediated diseases, with budoprutug as its lead product candidate.
• The company completed the acquisition of Tenet Medicines, Inc. on June 27, 2024, issuing 5,560,047 shares of common stock and incurring a $51.7 million expense for in-process research and development.
• A private placement of 31,238,282 shares of common stock at $3.84 per share generated gross proceeds of approximately $120 million.
• The company reported a net loss of $8.9 million for the three months ended September 30, 2024, and a net loss of $65.5 million for the nine months ended September 30, 2024.
• As of September 30, 2024, Climb Bio had cash, cash equivalents, and marketable securities totaling $217.9 million, which is expected to fund operations through 2027.
• The company plans to initiate a Phase 1b clinical trial of budoprutug for SLE and a Phase 2 clinical trial for ITP in the first half of 2025.
• Non-clinical data for a subcutaneous formulation of budoprutug is expected in the first half of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has a strong cash position and is advancing its lead candidate, the significant net losses and identified material weaknesses in internal control over financial reporting temper the positive aspects. The strategic shift and clinical trial plans are encouraging, but the company faces significant risks and uncertainties.

Positives

• The company has a strong cash position of $217.9 million, expected to fund operations through 2027.
• The company is advancing budoprutug into late phase clinical development for pMN in 2025.
• The company has received FDA clearance for its IND for budoprutug in SLE.
• The company has successfully formulated budoprutug to concentrations exceeding 175 mg/ml for subcutaneous administration.
• The company has observed dose-dependent B-cell depletion in tissues in preclinical studies.

Negatives

• The company reported a net loss of $65.5 million for the nine months ended September 30, 2024.
• The company incurred a $51.7 million expense for in-process research and development related to the Tenet acquisition.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company incurred restructuring costs of $3.3 million in connection with the cessation of operations in the U.K.

Risks

• The company has incurred significant losses since inception and anticipates substantial losses for the foreseeable future.
• The company will need substantial additional funding for its continuing operations.
• The company has never generated revenue from product sales and may never achieve or maintain profitability.
• The company's future success is dependent primarily on regulatory approval and commercialization of budoprutug.
• The company faces significant competition in an environment of rapid technological change.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• The company relies heavily on in-licensed patents and other intellectual property rights.
• The company has identified material weaknesses in its internal control over financial reporting.
• The trading price of the shares of the company's common stock has been and may continue to be volatile.

Future Outlook

The company estimates that its available cash, cash equivalents, and marketable securities will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of these unaudited condensed consolidated financial statements and the company anticipates that it will need to raise substantial financing in the future to fund its operations. The company plans to initiate a Phase 1b clinical trial of budoprutug for SLE and a Phase 2 clinical trial for ITP in the first half of 2025. Non-clinical data for a subcutaneous formulation of budoprutug is expected in the first half of 2025.

Management Comments

• Based on the results of the Phase 1b clinical trial of budoprutug in pMN and clearance from the FDA of our IND for budoprutug in SLE in October 2024, we plan to initiate a Phase 1b clinical trial of budoprutug for SLE in the first half of 2025.
• We also plan to initiate a Phase 2 clinical trial of budoprutug for ITP in the first half of 2025, subject to clearance of an IND or CTA.
• We are also advancing the subcutaneous formulation of budoprutug, with non-clinical data expected in the first half of 2025.
• We also plan to advance budoprutug into late phase clinical development for pMN in 2025.

Industry Context

The company's strategic shift to immune-mediated diseases reflects a growing focus in the biotechnology industry on developing targeted therapies for autoimmune and inflammatory conditions. The development of budoprutug, an anti-CD19 monoclonal antibody, aligns with the industry's interest in B-cell depletion therapies for a range of diseases.

Comparison to Industry Standards

• The company's cash runway through 2027 is relatively strong compared to many clinical-stage biotech companies, providing a longer period to achieve key milestones.
• The company's focus on budoprutug for pMN, ITP, and SLE is in line with the industry's interest in developing therapies for autoimmune diseases, but the company will face competition from other companies developing similar therapies.
• The company's plan to develop a subcutaneous formulation of budoprutug is a positive differentiator, as it offers a more convenient dosing option compared to intravenous treatments.
• The company's reported Phase 1b clinical trial results for budoprutug in pMN, with 60% of patients achieving complete remission of proteinuria, are promising and compare favorably to other early-stage clinical trials in this space.
• The company's decision to pause development of its Kv7 program is not uncommon in the biotech industry, where companies often need to prioritize their resources and focus on their most promising assets.

Management Changes

Related Party Transactions

• The company paid approximately $0.1 million to Sera Services for services provided under the Sera Services Agreement for the three and nine months ended September 30, 2024.
• For the three and nine months ended September 30, 2024, the company paid approximately $0.1 million to Blackbird under the Blackbird Service Agreement.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and market conditions.
• Employees may be affected by the company's restructuring and strategic shifts.
• Customers and patients may benefit from the development of new therapies for immune-mediated diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Initiate a Phase 1b clinical trial of budoprutug for SLE in the first half of 2025.
• Initiate a Phase 2 clinical trial of budoprutug for ITP in the first half of 2025.
• Advance the subcutaneous formulation of budoprutug, with non-clinical data expected in the first half of 2025.
• Advance budoprutug into late phase clinical development for pMN in 2025.

Key Dates

Keywords

budoprutug, immune-mediated diseases, clinical trials, biotechnology, monoclonal antibody, B-cell depletion, primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, regulatory approval